| 000 | 05365cam a2200409Ii 4500 | ||
|---|---|---|---|
| 001 | 95902 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102112727.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 170501s2017 ja a o 000 0 eng d | ||
| 020 |
_a443156523X _q(electronic bk.) |
||
| 020 |
_a9784431565239 _q(electronic bk.) |
||
| 020 | _z4431565213 | ||
| 020 |
_z9784431565215 _q(print) |
||
| 040 |
_aN$T _cN$T _dGW5XE _dEBLCP _dYDX _dUAB _dN$T _dMERER _dESU _dAZU _dUPM _dOCLCF _dCOO _dOCLCQ _dOTZ _dVT2 _dOCLCQ _dIOG _dU3W _dES-MaUEC _bspa |
||
| 050 | 4 |
_aRC643 _b2017 EB |
|
| 245 | 0 | 0 |
_aAdult T-cell leukemia/lymphoma _cToshiki Watanabe, Takuya Fukushima, editors. |
| 264 | 1 |
_aTokyo, Japan _bSpringer International Publishing _c2017 |
|
| 300 |
_a1 recurso en línea (viii, 169 páginas) _bilustraciones (algunas a color) |
||
| 336 |
_aTexto _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 505 | 0 | _aStandardization of Terminology; Formal Name of HTLV-1; Abbreviation of Adult T-Cell Leukaemia-Lymphoma; Contents; Chapter 1: Overview; Chapter 2: Human T-Cell Leukemia Virus Type 1 (HTLV-1); 2.1 Human T-Cell Leukemia Virus Type 1 (HTLV-1) as the First Human Retrovirus; 2.2 Genome Structure and Replication of HTLV-1; 2.2.1 Structural Genes; 2.2.2 Regulatory Proteins: Tax and Rex; 2.2.2.1 Transcriptional Activation of LTR by Tax; 2.2.2.2 Posttranscriptional Regulation of Viral RNA by Rex; 2.2.3 Accessory Proteins: HBZ, p30, p12, p13, and p8. | |
| 505 | 8 | _a2.2.3.1 Viral Persistence and HTLV-1-Related Pathogenesis by HBZ2.2.3.2 Posttranscriptional Regulation of Viral and Cellular RNA by p30; 2.2.3.3 Augmentation of Reactive Oxygen Production by p13; 2.2.3.4 Modulation of Signal Transduction and Immune Response by p12/p8; 2.3 Transmission; 2.4 Clonal Expansion and Immune Response; 2.5 Leukemogenesis by Tax and HBZ; 2.5.1 Activation of NF-kappaB; 2.5.2 Activation of the PI3K/AKT Pathway; 2.5.3 Modulation of TGF-beta/Smad and Wnt Signaling Pathways; 2.5.4 Enhancement of S Phase Entry and Cell Cycle Progression. | |
| 505 | 8 | _a2.5.5 Induction of Chromosomal Abnormality and DNA Damage2.6 Animal Model; 2.7 Perspective; References; Chapter 3: Epidemiology; 3.1 Introduction; 3.2 Prevalence, Incidence, and Lifetime Risk; 3.2.1 Prevalence and Geographic Distribution of HTLV-1; 3.2.2 Incidence of ATL in the General Population; 3.2.3 Incidence and Lifetime Risk of ATL Among HTLV-1 Carriers; 3.3 Risk Factors for ATL Development from HTLV-1 Carriers; 3.3.1 Host Susceptibility; 3.3.2 Immune System Abnormalities; 3.3.3 Laboratory Markers; 3.3.4 Provirus Load; 3.3.5 Provirus Integration Status. | |
| 505 | 8 | _a3.4 Transmission of HTLV-1 and Its Prevention3.4.1 Mother-to-Child Transmission and Its Prevention; 3.4.2 Sexual Transmission and Its Prevention; 3.4.3 Blood-Borne Transmission and Its Prevention; 3.5 Future Perspective; References; Chapter 4: Pathology; 4.1 Neoplastic Lesions; 4.1.1 Sites of Involvement; 4.1.2 Clinical Features: Peripheral Blood; 4.1.3 Lymph Node Lesions; 4.1.3.1 Lymphomatous Lesions; 4.1.3.1.1 Pleomorphic (Medium- and Large-Cell) Type; 4.1.3.1.2 Pleomorphic Small-Cell Type; 4.1.3.1.3 Anaplastic Large-Cell Type; 4.1.3.1.4 AILT-Like ATL. | |
| 505 | 8 | _a4.1.3.1.5 Immunophenotypes and Genotypes4.1.3.2 Atypical Lymphomatous and Nonlymphomatous Lesions; 4.1.3.2.1 Hodgkin Cell-Like Type; 4.1.3.2.2 Lymphadenitis Type; 4.1.3.3 Survival Rates; 4.1.4 Cutaneous Lesions; 4.1.5 Gastrointestinal Tract; 4.1.6 Liver; 4.1.7 Bone Marrow; 4.2 Nonneoplastic Lesions; 4.2.1 HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP); 4.2.2 HTLV-I-Associated Uveitis (HAU); 4.2.3 HTLV-I-Associated Bronchopneumopathy or Diffuse Panbronchiolitis (HAB); 4.2.4 Opportunistic Infections; References; Chapter 5: Immunophenotype. | |
| 520 | 3 | _aThis book provides essential information on the epidemiology, molecular and genetic features, anti-CCR4 antibody therapy and a nationwide study of transplantation on human T-leukemia virus type-I (HTLV-1) and adult T-cell leukemia/lymphoma (ATL). This rare but important disease has restricted endemic areas and distinct clinical features such as a high frequency of hypercalcemia, strong predisposition to infection and poor response to chemotherapy, aspects which set ATL apart from other types of non-Hodgkin lymphoma. Given the small number of patients, enrollment in clinical trials has not been feasible, and establishing treatment standard has been difficult but new evidence, such as results of nationwide studies on transplantation, have shown new insights and potential treatments. Based on recent evidence, the book presents new treatment methods for ATL and infection prevention of HTLV-1, enabling clinicians, researchers and post-docs specializing in hematology and virology to gain a valuable overview of the disease. | |
| 650 | 7 |
_aLinfocitos T _2embne _0(OCoLC)fst00797196 _0 _9144344 |
|
| 700 | 1 |
_aFukushima, Takuya, _eeditor literario |
|
| 700 | 1 |
_aWatanabe, Toshiki, _eeditor literario |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-4-431-56523-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 988 | _aSpringer_Medicine_2017 | ||
| 998 |
_b02/2018 _dz _e- _zSI |
||
| 999 |
_c95902 _d95902 _x1 |
||